Skip to content

NovoCure NVCR Inventory turnover

Inventory turnover at other companies

Boston Scientific logo
Boston ScientificBSX
2.1×+0.1×
Medtronic logo
MedtronicMDT
2.2×+0.1×
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
2.9×-0.5×
ALN
Alnylam PharmaceuticalsALNY
10.9×+6.9×
BridgeBio Pharma logo
BridgeBio PharmaBBIO
1.5×
Exelixis logo
ExelixisEXEL
1.2×+0.2×

Other financials

Income statement

See full
Revenue$174.1M+12.3%
Gross profit$135.1M+16.0%
Operating income-$67.4M-78.1%
Net income-$71.1M-107%
EPS (diluted)-$0.62-100%

Balance sheet

See full
Cash & equivalents$87.5M-31.2%
Total debt$39.5M-2.1%
Total equity$330.7M-8.6%
Total assets$787.9M-36.9%

Cash flow

See full
Operating cash flow-$13.5M+62.1%
CapEx$5.2M-51.4%
Free cash flow-$18.7M+59.7%

Valuation

See full
Market cap$1.7B-36.7%

Profitability

See full
Gross margin75.2%-2.0pp
Operating margin-27.2%+0.4pp
Net margin-25.7%-0.7pp
FCF margin-7.1%-2.0pp

Returns & leverage

See full
Return on equity-50%+5.4pp
Debt / equity0.1×0.0×
Current ratio2.9×+1.4×

Where this comes from

Calculated from NovoCure’s reported figures.

Based on trailing twelve months.

The official record: NovoCure’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about NovoCure's inventory turnover.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is NovoCure's inventory turnover?
NovoCure (NVCR) reported inventory turnover of 4× in Q1 2026.
How has NovoCure's inventory turnover changed year-over-year?
NovoCure's inventory turnover increased by 16.3% year-over-year, from 3.5× to 4×.
What is the long-term trend for NovoCure's inventory turnover?
Over 5 years (2020 to 2025), NovoCure's inventory turnover has grown at a 1.0% compound annual growth rate (CAGR), from 4.2× to 4.4×.
What does inventory turnover mean?
Trailing-twelve-month cost of revenue divided by average inventory. Measures how many times inventory is sold and replaced over the year.